Doctors prescribe three main categories of medication for atrial fibrillation (AFib): blood thinners to prevent stroke, rate control drugs to slow the heart, and rhythm control drugs to restore a normal heartbeat. Most people with AFib end up on at least two of these, often a blood thinner paired with either a rate or rhythm control medication. The specific combination depends on your symptoms, how long you’ve had AFib, and whether you have other heart conditions.
Blood Thinners for Stroke Prevention
AFib allows blood to pool in the heart’s upper chambers, which can form clots that travel to the brain. Preventing stroke is the single most important part of AFib treatment, and for most people that means taking a blood thinner long-term.
Direct oral anticoagulants (DOACs) are now the preferred choice over warfarin for most patients. The four available options are apixaban, rivaroxaban, dabigatran, and edoxaban. In pooled research data, DOACs reduced stroke risk by about 34% compared to warfarin, while also lowering the risk of major bleeding by roughly 30%. Among the individual drugs, apixaban showed the most significant reduction in major bleeding events, which is one reason it has become the most widely prescribed of the group.
Not everyone with AFib needs a blood thinner. Doctors use a scoring system called CHA2DS2-VASc that assigns points for risk factors like age over 65, high blood pressure, diabetes, heart failure, prior stroke, and vascular disease. Men with a score of 2 or higher (or women with 3 or higher) are generally started on long-term anticoagulation. At the borderline, with just one non-sex risk factor, the decision becomes a conversation between you and your doctor about your personal risk.
Dose Adjustments for Kidney Function
Your kidneys clear most DOACs from your body, so reduced kidney function changes which drug and dose you receive. When kidney filtration drops below a certain threshold (roughly half of normal), doctors typically switch to a lower dose of edoxaban or rivaroxaban. Apixaban uses a different approach: dose reduction kicks in only when you meet at least two of three criteria, being 80 or older, weighing 132 pounds (60 kg) or less, or having elevated creatinine levels. This makes apixaban one of the more flexible options for people with kidney issues.
Rate Control Medications
Rate control doesn’t fix the irregular rhythm. Instead, it slows the heart rate so the ventricles (the heart’s main pumping chambers) don’t beat too fast. For many people, especially those with mild or no symptoms, rate control is the first treatment step.
The most common rate control drugs fall into two groups. Beta-blockers, such as metoprolol, slow the heart by blocking adrenaline signals. Calcium channel blockers like diltiazem and verapamil work by relaxing the electrical pathways between the upper and lower chambers of the heart. Both classes bring the resting heart rate down to a more comfortable range, usually under 110 beats per minute as an initial target. Digoxin is an older option sometimes added when beta-blockers or calcium channel blockers alone aren’t enough, particularly in people with heart failure.
Your doctor chooses between these based on your blood pressure and other conditions. Beta-blockers tend to be preferred if you also have heart failure or coronary artery disease. Calcium channel blockers work well for people with lung conditions like asthma, where beta-blockers can cause problems.
Rhythm Control Medications
Rhythm control aims to restore and maintain a normal heart rhythm. Recent evidence has shifted thinking significantly in this area. The landmark AFFIRM trial in 2002 found no survival advantage to rhythm control, so for years many doctors defaulted to rate control alone. But the EAST-AFNET 4 trial, published nearly two decades later, showed that early rhythm control actually reduces serious cardiovascular complications in people recently diagnosed with AFib. Current guidelines now emphasize maintaining normal rhythm and minimizing the total time spent in AFib.
For people with structurally normal hearts (no thickened walls, no heart failure), the first-line options are flecainide, propafenone, dronedarone, or sotalol. These drugs have fewer side effects outside the heart compared to stronger alternatives. Flecainide is particularly effective and can even be used as a single “pill-in-the-pocket” dose of 300 mg to stop an AFib episode on the spot, rather than taking medication every day.
If those first-line drugs don’t work, or if you have heart failure or significant thickening of the heart wall, amiodarone becomes the go-to choice. It is the most potent antiarrhythmic drug available and one of the few proven safe in heart failure. The tradeoff is a long list of potential side effects involving the thyroid, liver, lungs, skin, and eyes. People on amiodarone need blood tests for liver and thyroid function at least every six months, along with regular eye exams and lung monitoring.
Catheter Ablation as a First-Line Option
Ablation isn’t a medication, but it now holds a central place in AFib prescribing decisions. The 2023 joint guidelines from the American College of Cardiology and American Heart Association upgraded catheter ablation to a first-line treatment for selected patients, putting it on equal footing with drugs rather than reserving it as a backup. During the procedure, a specialist threads a thin catheter into the heart and uses heat or cold energy to create small scars that block the erratic electrical signals causing AFib.
The upgrade was driven by randomized trials showing ablation outperforms drug therapy for rhythm control in appropriately selected patients. It received the strongest possible recommendation (Class 1) for people with heart failure and a weakened pumping function, where ablation has shown clear benefits over medication alone. For others, ablation is a reasonable first choice if they prefer to avoid long-term antiarrhythmic drugs or if initial medications haven’t controlled symptoms.
What Treatment Looks Like in Practice
A newly diagnosed AFib patient typically leaves the doctor’s office with two prescriptions: a blood thinner (most commonly apixaban or rivaroxaban) and a rate control drug like metoprolol. If symptoms persist, meaning you still feel palpitations, fatigue, or shortness of breath despite a controlled heart rate, the conversation shifts to rhythm control. That might mean adding flecainide or another antiarrhythmic, or discussing ablation.
The choice between rate and rhythm control often comes down to how much AFib affects your daily life. Someone who barely notices their irregular heartbeat may do well on a beta-blocker and blood thinner indefinitely. Someone who feels wiped out every time their heart goes out of rhythm is more likely to benefit from aggressive rhythm control early on. Age, other health conditions, and personal preference all factor into that decision. Treatment isn’t static either. Many people start with one approach and adjust over months or years as symptoms change or new episodes develop.
One important point: even if rhythm control restores a normal heartbeat, most people still need to continue their blood thinner. AFib can return silently, without symptoms, and the stroke risk doesn’t disappear just because the heart seems to be in rhythm.